MedTrace Logo

Efficacy and Safety of Cortex Eucommiae (CE: Eucommia Ulmoides Oliver Extract) in Subjects With Mild Osteoarthritis

NCT03744611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-07-25

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of Cortex Eucommiae (CE: Eucommia ulmoides Oliver extract) in subjects with mild osteoarthritis (OA).

Conditions

Interventions

DIETARY_SUPPLEMENT

CE

550mg capsule (Eucommia ulmoides Oliver extract)

DIETARY_SUPPLEMENT

Placebo

550mg capsule (Placebo)

Sponsors & Collaborators

  • Jaseng Medical Foundation

    lead OTHER

Principal Investigators

  • Hyeon Yeong Ahn, PhD · Jaseng Medical Foundation

  • Jae-Heung Cho, KMD,PhD · Kyung Hee University at Gangdong

  • Dongwoo Nam, KMD,PhD · Kyunghee University

  • Eun-Jung Kim, KMD,PhD · DongGuk University

  • In-Hyuk Ha, KMD,PhD · Jaseng Medical Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-22
Primary Completion
2019-09-05
Completion
2019-09-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03744611 on ClinicalTrials.gov